V ascular injury and thrombosis play a central role in cardiovascular diseases such as myocardial infarction, stroke, and venous thromboembolism. Platelets respond to vascular injury by exocytosis, releasing prothrombotic factors such as von Willebrand factor (vWF) that mediates platelet adherence to the vessel wall. Plasma vWF levels are associated with thrombosis and the risk of cardiovascular events. 1 achieved. However, the genetic techniques using the CRISPR/ Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated 9) system permit the rapid generation of novel animal models. [13] [14] [15] Precise genome editing can be achieved by the CRISPR/Cas9 system, which comprised of a Cas9 endonuclease mRNA, a single-guide RNA that directs Cas9-mediated DNA double-strand break at the genomic region of interest, and an exogenous single-strand donor oligonucleotide on which desired mutation can be synthesized and integrated into double-strand break site by homologydirected repair. [16] [17] [18] The unprecedented ease and efficiency of the CRISPR/Cas9 system has permitted us to investigate the effect of a specific STXBP5 genetic variant on exocytosis and thrombosis in vivo.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results
We first determined the individual SNPs identified by the Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium that are most likely to affect STXBP5 function. The STXBP5 SNP associated with altered vWF levels with the highest genome-wide significance (P=1.16×10 −22 ) is rs9390459 (hg19 chr6: g.147680359 G>A), a synonymous variant in STXBP5. 2 Although synonymous, it is conceivable that rs9390459 could affect STXBP5 function via epigenetic mechanisms. Alternatively, the SNP may serve as a proxy that links to other causal, nonsynonymous variants responsible for changes in vWF levels via post-transcriptional mechanism.
19 Therefore, we searched for possible explanations for how the synonymous variant rs9390459 might affect vWF levels and thrombosis: potential epigenetic effects, potential enhancer effects, gene dosage effect via expression quantitative trait loci, or potential linkage disequilibrium with nonsynonymous variants.
First, we searched for a potential link between rs9390459 and epigenetic features by examining rs9390459 in the UCSC genome browser, seeking potential chromatin modifications, including methylation and acetylation or transcription factor binding sites. Among all 7 cell types (GM12878, H1-hESC, HSMM, HUVEC, K562, NHEK, and NHLF) of the Encyclopedia of DNA Elements Project, 20 the genomic DNA containing SNP rs9390459 is uniformly devoid of histone markers that are associated with gene expression or transcriptional regulation. Furthermore, among 161 transcription factors assayed by Encyclopedia of DNA Elements, no transcription factor binding signals were identified in the cell type (HUVEC) relevant to plasma vWF ( Figure I in the online-only Data Supplement). The annotations of the noncoding genome at rs9390459 are also unremarkable for endothelial cells in HaploReg (http://archive.broadinstitute.org/ mammals/haploreg/haploreg.php). 21 We also did not detect microRNA, lncRNA, or predicted genes that overlap with or near rs9390459 besides STXBP5 (data not shown).
Next, we investigated possible interactions of rs9390459 with distal DNA because noncoding DNA variants can interact with distant enhancers, leading to human disease. 22 We investigated potential DNA 3-dimensional interactions of rs9390459 using genome-wide in situ Hi-C data mapped on HUVEC with kilobase resolution. 23 Within an ≈7 million bp genomic DNA window flanking rs9390459, putative DNA looping structures can be recognized with experimentally identified DNA contact domains. However, rs9390459 is not associated with DNA loop anchors, contact domains, or distinct patterns of histone markers linked to promoters or enhancers ( Figure II in the online-only Data Supplement). Although Hi-C technique captures interactions genome wide, 24 it does not provide functional information of the contacting sites and is undermined by low resolution. Therefore, we searched for data sets of chromatin interaction analysis with paired-end tag sequencing that focus on parts of the genome that have chromatin-binding proteins and functional implications in high resolution. 25 Using the well-annotated chromatin interaction analysis with paired-end tag sequencing data sets on human K562 cells, distal chromatin interactions were found associated with insulator protein (CTCF), the transcription machinery (RNA-Pol II), and chromosome repair and cohesion machinery (RAD21) outside of rs9390459 ( Figure III in the online-only Data Supplement). The locus of rs9390459 is found in a region that lacks distal chromatin interaction associated with these proteins. Together with HUVEC Hi-C data, the evidence does not support that rs9390459 is likely to affect the STXBP5 locus via distal chromatin interactions.
We then searched for expression quantitative trait loci using the Genotype-Tissue Expression project data (http:// www.gtexportal.org/home/) containing 8555 genome-wide gene expression profiles in 53 human tissues. 26 SNP rs9390459 is not significantly correlated with any gene expression trait in any profiled tissue. Taken together, our data do not support rs9390459 as a causal variant that affects DNA epigenetic modification, transcriptional factor binding, distal interactions, or expression quantitative traits.
Finally, we searched for nonsynonymous variants that are in high linkage disequilibrium with the leading SNP rs9390459. Using data from 1000 Genomes Project (Phase 3 V5, European ancestry), we identified 56 SNPs that are in linkage disequilibrium with rs9390459 (R 2 >0.8). 27 These SNPs lie within a 193 kb genomic segment overlapping STXBP5 ( Figure IV in the online-only Data Supplement). Only 1 of these 56 SNP is a nonsynonymous SNP, rs1039084 (hg19 chr6: g.147635413 A>G). This nonsynonymous SNP rs1039084 is in high linkage disequilibrium (R 2 =0.92) with rs9390459 ( Figure V in the online-only Data Supplement).
The nonsynonymous SNP rs1039084 encodes STXBP5 asparagine to serine substitution at position 436 in the WD40 repeat domain of STXBP5, a domain that regulates exocytosis in various cell types. [28] [29] [30] [31] [32] [33] [34] [35] We designate this mutation as follows: STXBP5(N436S).
Human studies show that the nonsynonymous SNP rs1039084 minor allele G is associated with decreased vWF levels, decreased venous thrombosis risk, and increased bleeding. 4, 8, 9 These genetic and clinical studies suggest that this specific STXBP5 variant may affect STXBP5 function.
To identify the functional significance of the human mutation STXBP5(N436S), we previously knocked down the endogenous STXBP5 expression in cultured human endothelial cells and found overexpression of STXBP5(N436S) decreased vWF exocytosis more than wild-type (WT) STXBP5. 10 To further explore the physiological relevance of the STXBP5(N436S) mutation in vivo, we created a mouse model of this genetic variant. Mouse STXBP5 is 98% identical to human STXBP5, and mouse STXBP5(N437) corresponds to human STXBP5(N436). We used CRISPR/Cas9 techniques to change the WT murine allele AAT encoding 437Asn to human AGC allele encoding 437Ser, generating a mouse designated as Stxbp5(N437S). 16 We knocked the rs1039084 minor allele of human STXBP5 into the orthologous mouse Stxbp5 locus by CRISPR/Cas9 genome editing. 15, 18 Injection into murine zygotes of Streptococcus pyogenes Cas9 (SpCas9) mRNA, purified single-guide RNA targeting 437Asn, and a singlestrand donor oligonucleotide bearing the human rs1039084 minor allele for homology-directed repair, generated 1 of 50 pups with 1 allele precisely edited into the human minor allele AT>GC (Figure 1A and 1B; Table II in the online-only Data Supplement). Precise editing was confirmed by Sanger sequencing ( Figure 1C ) and by restriction fragment length polymorphism analysis ( Figure 1D ). The mutant allele was transmitted through the germline, as assayed by a novel multiplex polymerase chain reaction assay we recently developed ( Figure 1E ). 18 We assessed potential mutations that could be caused by CRISPR/Cas9 editing that might lie outside of the Stxbp5 locus. We examined 24 genomic loci with ≤4 mismatched We proceeded to study the effect of the human variant on vWF levels, hemostasis, and thrombosis, using 4-to 8-week-old male mice that were Stxbp5(N437S) and their WT littermates.
In humans, the nonsynonymous SNP rs1039084 is associated with a decrease in vWF levels. 4, 8 We tested the effect of STXBP5(N437S) on vWF levels in mice. vWF levels are lower in homozygous (437S/S) mutant mice than WT mice (Figure 2A) .
In humans, the nonsynonymous SNP rs1039084 is associated with an ≈20% decreased risk of venous thrombosis. 9 Therefore, we next tested the effect of STXBP5(N437S) on hemostasis in mice. Compared with WT mice, heterozygous (437N/S) and homozygous (437S/S) mutant mice displayed prolonged bleeding time ( Figure 2B ).
We then explored the effect of STXBP5(N437S) on thrombosis in large and small arteries. First, we used a Doppler probe to measure the changes in blood flow in the murine carotid artery after FeCl 3 -induced injury. Carotid flow diminished steadily after FeCl 3 injury in WT mice, resulting in rapid and complete vessel occlusion ( Figure 2C and 2D) . However, the time to complete carotid occlusion was longer in Stxbp5(N437S) carrier mice than in WT mice ( Figure 2C and  2D) . We further characterized the thrombotic phenotype in the microvasculature in a murine mesenteric thrombosis model. Although the time to form a small (50 μm diameter) thrombus was not affected by the Stxbp5(N437S) mutation, mice carrying this allele had severely delayed time for complete vessel occlusion in mesenteric arterioles and venules ( Figure 2E and 2F). Taken together, these data suggest that the genetic variant Stxbp5(N437S) decreases thrombosis.
We then tested the effect of STXBP5(N437S) on platelets because previous studies show STXBP5 is required for platelet secretion. 10, 11 Stimulation of murine platelets with the physiological agonist thrombin induced dose-dependent granule secretion, as measured by platelet factor 4 release from α-granules ( Figure 3A) , and ATP and serotonin release from dense granules ( Figure 3B and 3C) . Platelets from Stxbp5(N437S) mice displayed significantly impaired granule secretion ex vivo in response to low-dose thrombin, an effect that gradually diminished with increasing thrombin doses ( Figure 3A through 3C) . Furthermore, platelet spreading is less in platelets from Stxbp5(N437S) mice than in platelets from WT mice ( Figure 3D ; Figure VI in the online-only Data Supplement), a statistically significant effect that is probably not biologically significant ( Figure 3D ). These data suggest that STXBP5(N437S) causes a platelet secretion defect.
Taken together, our current study provides functional evidence for the regulatory role of a genetic variant linked by GWAS to altered thrombosis. 2, 4, 5, 8 Consistent with the lower plasma vWF, prolonged bleeding, and decreased venous thrombosis observed in human carriers of the rs1039084 minor allele, 4, 8, 9 Stxbp5(N437S) mice had lower plasma vWF, prolonged bleeding, and decreased thrombosis. Our data suggest that these abnormalities are due in part to decreased plasma vWF and functional defects of Stxbp5(N437S) platelets.
Discussion
The major finding of our study is that a human mutation in STXBP5 linked to vWF levels and thrombosis causes a thrombotic phenotype in mice. We used CRISPR/Cas9 gene editing to create a mouse model of human genetic variation. Mice carrying the minor allele of human SNP rs1039084 at an orthologous locus had decreased vWF exocytosis, decreased thrombosis, increased bleeding, and decreased platelet secretion. Thus, our current study provides strong functional evidence for the regulatory role of a GWAS-derived variant on human bleeding and thrombosis phenotype. 2, 4, 5, 8 We show that the genetic variation in STXBP5(N436) decreases platelet secretion ex vivo, but the precise mechanisms are not yet known. SNP rs1039084 encodes N436S in the second N-terminal WD40 repeat of STXBP5, and WD40 domain has been shown to participate in the inhibition of exocytosis. mutation within this region may interfere with STXBP5 interactions with synaptotagmin or syntaxin or may create a novel site for post-translational modification. [31] [32] [33] [34] [35] Our data showed murine heterozygotes displayed changes comparable to Stxbp5(N437S) homozygotes, supporting the observations in humans that STXBP5(N436) may act in a gain-of-function manner. 8, 9 vWF levels are significantly lower in STXBP5(N437) mouse plasma than in WT mouse plasma (Figure 2A ). This murine phenotype recapitulates the human phenotype because rs1039084 is associated with lower plasma vWF levels in humans. 4, 8 The effect of this SNP on vWF levels is even greater in subjects with coronary artery disease or stroke or peripheral arterial disease than in healthy control subjects. 4 The underlying causes of this increased effect of mutations in STXBP5 on vWF levels in subjects with arterial disease are unclear. Further studies in human subjects are needed to clarify the relationship between rs1039084 and vWF levels and atherosclerosis.
One limitation of the study is that currently there is no effective method to identify off-target mutations in genome-edited animals. 15 Off-target surveys such as GUIDE-seq found that in cells the majority of off-target sites were not detected by computational methods, and robust experiment-based off-target detection is required to efficiently identify real off-target edits. 36 However, genome-sequencing-based evaluation showed that off-target mutations are rare in Cas9-modified mice. Even if off-targets are occasionally found in the Cas9-modified founder mouse, they can be readily bred away by crossing with WT animals 18 or completely avoided by simply generating a new mouse line using an alternative guide RNA. There are important strategies to limit off-targets in animal genome-targeting design. 15, 37 In addition, the advantage of a genome-edited animal model is that any off-target effects can be effectively controlled by using littermate controls. The potential off-target effects from this study are likely to be insignificant, although robust off-target detection methods such as GUIDE-seq in an in vivo setting would be highly informative to accurately assess the off-target effects of future genome-edited mouse models.
In conclusion, our study reveals the functional relevance of a candidate SNP identified by GWAS. Our data suggest that genetic variation within STXBP5 is a genetic risk for bleeding and thrombotic diseases in humans. Our study demonstrates that CRISPR/Cas9 gene editing in mice is a rapid approach to studying the functional significance of genetic variants associated with thrombosis. This approach permits efficient, inexpensive, and rigorous disease modeling in animals, paving the way for rapidly testing the functional consequences and clinical relevance of genetic variations that are linked to human vascular diseases.
